Showing results (381-390 of 401) with videos related to
Sort By:
Pageof 41
Neurology|April 24, 2002
Clinical features of frontotemporal dementia due to the intronic tau 10(+16) mutationJ C Janssen, E K Warrington, H R Morris, et al.Nature Communications|August 19, 2018
Galectin-9 suppresses B cell receptor signaling and is regulated by I-branching of N-glycansN Giovannone, J Liang, A Antonopoulos, et al.Journal of Neurology, Neurosurgery, and Psychiatry|February 28, 2002
Sequence analysis of tau in familial and sporadic progressive supranuclear palsyH R Morris, R Katzenschlager, J C Janssen, et al.Leukemia|February 12, 2010
SHIP-1 inhibits CD95/APO-1/Fas-induced apoptosis in primary T lymphocytes and T leukemic cells by promoting CD95 glycosylation independently of its phosphatase activityE Charlier, C Condé, J Zhang, et al.Brain : a Journal of Neurology|October 24, 2001
A clinical and pathological study of motor neurone disease on GuamH R Morris, S Al-Sarraj, C Schwab, et al.Hypertension (Dallas, Tex. : 1979)|December 24, 1997
Hypothalamic hypertensive factor: an inhibitor of nitric oxide synthase activityH R Morris, A T Etienne, M Panico, et al.Brain Communications|May 23, 2022
A data-driven model of brain volume changes in progressive supranuclear palsyW J Scotton, M Bocchetta, E Todd, et al.Journal of Neurology, Neurosurgery, and Psychiatry|January 16, 2015
A panel of nine cerebrospinal fluid biomarkers may identify patients with atypical parkinsonian syndromesN K Magdalinou, R W Paterson, J M Schott, et al.Archives of Neurology|November 16, 2001
The genetic and pathological classification of familial frontotemporal dementiaH R Morris, M N Khan, J C Janssen, et al.Parkinsonism & Related Disorders|February 19, 2017
Identification of candidate cerebrospinal fluid biomarkers in parkinsonism using quantitative proteomicsN K Magdalinou, A J Noyce, R Pinto, et al.Pageof 41